Patients with 15-day MRD less than 10% blasts fared better than those with 10% or greater, even if they had other high-risk factors.

Topline data were announced from a phase 3 trial evaluating obinutuzumab in adults with systemic lupus erythematosus on standard therapy.

Tier 1 aberrations, which are classified as those having well-established prognostic, diagnostic, or therapeutic relevance according to guidelines set by medical societies such as WHO, NCCN and ICC, ...

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton ...

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately ...

A Northwestern team transformed a common chemotherapy drug into a powerful, targeted cancer therapy using spherical nucleic ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to M2T-CD33 (LTI-214) for the treatment of ...

Researchers sought to determine whether brexucabtagene autoleucel would improve response rates among patients with relapsed or refractory CLL.

CERo Therapeutics Holdings, Inc., (OTC PINK: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces the ...

Eight-year-old Kim Yoo-na, who battled leukemia, returned to school after receiving innovative CAR-T therapy funded by ...

A hidden structure inside the cell is rewriting how scientists understand leukemia. Beneath the microscope, what looked like ...

Study reshapes view of how a common leukemia begins and could point to new therapeutic strategies targeting a common weakness.